The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor:In vivo expression and antitumor activity
Open accessAbstract
Neuropilin-1 (NRP1) is a 130-kDa transmembrane receptor for semaphorins, mediators of neuronal guidance, and for vascular endothelial growth factor 165 (VEGF 165), an angiogenesis factor. A 2.2-kb truncated NRP1 cDNA was cloned that encodes a 644-aa soluble NRP1 (sNRP1) isoform containing just the a/CUB and b/coagulation factor homology extracellular domains of NRP1. sNRP1 is secreted by cells as a 90-kDa protein that binds VEGF 165, but not VEGF 121. It inhibits 125 I-VEGF 165 binding to endothelial and tumor cells and VEGF 165-induced tyrosine phosphorylation of KDR in endothelial cells. The 3′ end of sNRP1 cDNA contains a unique, 28-bp intron-derived sequence that is absent in full-length NRP1 cDNA. Using a probe corresponding to this unique sequence, sNRP1 mRNA could be detected by in situ hybridization differentially from full-length NRP1 mRNA, for example, in cells of liver, kidney, skin, and breast. Analysis of blood vessels in situ showed that NRP1, but not sNRP1, was expressed. sNRP1 was functional in vivo. Unlike control tumors, tumors of rat prostate carcinoma cells expressing recombinant sNRP1 were characterized by extensive hemorrhage, damaged vessels, and apoptotic tumor cells. These results demonstrate the existence of a naturally occurring, soluble NRP1 that is expressed differently from intact NRP1 and that appears to be a VEGF 165 antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Self-citationPlate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275
Kendall, R. L., & Thomas, K. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10705 · Cited by 1,394
In situ hybridization; a practical approach
(1993) · International Journal of Biochemistry · doi:10.1016/0020-711x(93)90093-t · Cited by 1,220
Neuropilin Is a Semaphorin III Receptor
Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y.-T., Giger, R. J., & Ginty, D. D. (1997) · Cell · doi:10.1016/s0092-8674(00)80535-8 · Cited by 1,180
Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III
He, Z., & Tessier-Lavigne, M. (1997) · Cell · doi:10.1016/s0092-8674(00)80534-6 · Cited by 1,142
Kendall, R. L., Wang, G., & Thomas, K. A. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1355 · Cited by 724
Cited by
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
VEGF Receptor Signal Transduction
Matsumoto, T., & Claesson-Welsh, L. (2001) · Science's STKE · doi:10.1126/stke.2001.112.re21 · Cited by 502
Neuropilins: structure, function and role in disease
Pellet-Many, C., Frankel, P., Jia, H., & Zachary, I. (2008) · Biochemical Journal · doi:10.1042/bj20071639 · Cited by 395
Vascular endothelial growth factor family of ligands and receptors: Review
Otrock, Z. K., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2006.12.003 · Cited by 376
VEGF: an update on biological and therapeutic aspects
Ferrara, N. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00153-1 · Cited by 372
Signalling by semaphorin receptors: cell guidance and beyond
Tamagnone, L., & Comoglio, P. M. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01816-x · Cited by 354
Neufeld, G. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00140-2 · Cited by 350
A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response
Tordjman, R., Lepelletier, Y., Lemarchandel, V., Cambot, M., Gaulard, P., Hermine, O., & Roméo, P.-H. (2002) · Nature Immunology · doi:10.1038/ni789 · Cited by 322
Neuropilin‐1 expression by tumor cells promotes tumor angiogenesis and progression
Miao, H., Lee, P., Lin, H., Soker, S., & Klagsbrun, M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0250com · Cited by 312
Self-citationWhitaker, G. B., Limberg, B. J., & Rosenbaum, J. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102315200 · Cited by 294
Zeng, H., Dvorak, H. F., & Mukhopadhyay, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103213200 · Cited by 294
Bielenberg, D. R., Hida, Y., Shimizu, A., Kaipainen, A., Kreuter, M., Kim, C. C., & Klagsbrun, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421378 · Cited by 286
Self-citationKuo, C. J., Farnebo, F., Yu, E. Y., Christofferson, R., Swearingen, R. A., Carter, R., von Recum, H. A., Yuan, J., Kamihara, J., Flynn, E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081615298 · Cited by 271
The role of neuropilins in cancer
Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0538 · Cited by 263
Mamluk, R., Gechtman, Z., Kutcher, M. E., Gasiunas, N., Gallagher, J., & Klagsbrun, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200730200 · Cited by 260
Self-citationNeuropilins in neoplasms: Expression, regulation, and function
Bielenberg, D. R., Pettaway, C. A., Takashima, S., & Klagsbrun, M. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.024 · Cited by 255
Self-citationNeuropilin 1: function and therapeutic potential in cancer
Chaudhary, B., Khaled, Y. S., Ammori, B. J., & Elkord, E. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1500-0 · Cited by 233
McFarland, T. J., Zhang, Y., Atchaneeyaskul, L.-O., Francis, P., Stout, J. T., & Appukuttan, B. (2006) · Plasmid · doi:10.1016/j.plasmid.2005.11.005 · Cited by 26
Metadata
- Authors
- Gagnon, M. L., Bielenberg, D. R., Gechtman, Z., Miao, H.-Q., Takashima, S., Soker, S., & Klagsbrun, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-02-25
- Volume
- 97
- Issue
- 6
- Pages
- 2573-2578
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2022950801
- Cited by
- 313
- References
- 33
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.